|
See related Videx EC enteric-coated cap information |
|
|
|
Manufacturer |
Bristol-Myers Squibb |
|
Distributor |
DKSH |
|
Contents |
Didanosine (ddI) |
|
Indications |
Treatment of HIV-infected patients in appropriate antiretroviral regimen, including use in combination w/ other NRTIs, NNRTIs & PIs. |
|
Dosage |
Adult ≥60 kg 400 mg once daily, <60 kg 250 mg once daily. |
|
Administration |
Should be taken on an empty stomach (Take on an empty stomach at least 2 hr after meals. Swallow whole, do not chew/crush.). |
|
Contraindications |
Previous hypersensitivity. |
|
Adverse Drug Reactions |
Reversible pancreatitis, peripheral neuropathy.
View ADR Monitoring Form |
|
Drug Interactions |
Drugs that cause peripheral neuropathy or pancreatitis.
View more drug interactions with Videx EC |
|
Pregnancy Category (US FDA) |
Category B: Either animal-reproduction studies have not demonstrated a foetal risk but there are no controlled studies in pregnant women or animal-reproduction studies have shown an adverse effect (other than a decrease in fertility) that was not confirmed in controlled studies in women in the 1st trimester (and there is no evidence of a risk in later trimesters). |
|
Presentation/Packing |
|
Form |
Packing |
Photo |
|
Videx EC enteric coated capsule |
|
Videx EC 250 mg x 30's |
 |
|
Videx EC 400 mg x 30's |
 |
|
|
|
Manufacturer: |
Bristol-Myers Squibb |
|
Distributor: |
DKSH
|
|
|
|
